| Revision as of 12:16, 24 October 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').← Previous edit |
Latest revision as of 04:29, 2 October 2023 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,800 edits consistent citation formatting |
| (16 intermediate revisions by 12 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| verifiedrevid = 447722875 |
|
| verifiedrevid = 457135624 |
|
| image = |
|
| image = |
|
⚫ |
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu/o |
|
| source = zu/o |
|
| target = ] beta |
|
| target = ] beta |
|
⚫ |
<!-- Clinical data --> |
|
|
|
|
⚫ |
| tradename = |
| ⚫ |
<!--Clinical data--> |
|
| ⚫ |
| tradename = |
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
|
|
| bioavailability = |
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
| metabolism = |
|
|
⚫ |
| excretion = |
| ⚫ |
| elimination_half-life = |
|
|
⚫ |
<!-- Identifiers --> |
| ⚫ |
| excretion = |
|
|
⚫ |
| CAS_number_Ref = {{cascite|changed|??}} |
|
|
|
|
⚫ |
| CAS_number = 267227-08-7 |
| ⚫ |
<!--Identifiers--> |
|
| ⚫ |
| CAS_number_Ref = {{cascite|correct|??}} |
|
| ⚫ |
| CAS_number = <!-- blanked - oldvalue: 267227-08-7 --> |
|
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| UNII = G88KCP51RE |
|
| UNII = G88KCP51RE |
| Line 42: |
Line 39: |
|
| KEGG = D02967 |
|
| KEGG = D02967 |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
|
| chemical_formula = |
| ⚫ |
<!--Chemical data--> |
|
|
| chemical_formula = |
|
| molecular_weight = |
|
|
|
|
| molecular_weight = |
|
|
}} |
|
}} |
|
'''Apolizumab''' is a humanized ] that is being studied as a treatment for hematologic ]s.<ref>{{cite journal | title = Gateways to clinical trials. | journal = Methods Find Exp Clin Pharmacol | volume = 25 | issue = 9 | pages = 747–71 | year = 2003 | pmid = 14685303 | author1 = Bayes M | author2 = Rabasseda X | author3 = Prous J | author-separator = ,}}</ref><ref>{{cite journal|pmid=17071489|year=2006|last1=Rech|first1=J|last2=Repp|first2=R|last3=Rech|first3=D|last4=Stockmeyer|first4=B|last5=Dechant|first5=M|last6=Niedobitek|first6=G|last7=Gramatzki|first7=M|last8=Valerius|first8=T|title=A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.|volume=47|issue=10|pages=2147–54|doi=10.1080/10428190600757944|journal=Leukemia & lymphoma}}</ref> |
|
'''Apolizumab''' is a humanized ] intended for use in hematologic ]s.<ref>{{cite journal | vauthors = Bayes M, Rabasseda X, Prous JR | title = Gateways to clinical trials | journal = Methods and Findings in Experimental and Clinical Pharmacology | volume = 25 | issue = 9 | pages = 747–771 | date = November 2003 | pmid = 14685303 }}</ref><ref>{{cite journal | vauthors = Rech J, Repp R, Rech D, Stockmeyer B, Dechant M, Niedobitek G, Gramatzki M, Valerius T | display-authors = 6 | title = A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study | journal = Leukemia & Lymphoma | volume = 47 | issue = 10 | pages = 2147–2154 | date = October 2006 | pmid = 17071489 | doi = 10.1080/10428190600757944 | s2cid = 24080973 }}</ref> Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were ] and ].<ref>{{cite journal | vauthors = Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC | display-authors = 6 | title = A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia | journal = Leukemia & Lymphoma | volume = 50 | issue = 12 | pages = 1958–1963 | date = December 2009 | pmid = 19860603 | pmc = 8166408 | doi = 10.3109/10428190903186486 | s2cid = 22328921 }}</ref> |
|
|
|
|
|
==References== |
|
== References == |
|
{{reflist}} |
|
{{reflist}} |
|
|
|
|
|
{{Monoclonals for immune system}} |
|
{{Monoclonals for immune system}} |
|
|
|
|
|
|
] |
|
|
] |
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |